Furthermore, RUNX1mut BP-CML showed aberrant expression of lymphoid antigens (CD19, CD7) in myeloid-BP patients and overexpression of lymphoid TFs and markers similar to RUNX1mut AML [47]. This evidence concerns the gene CD19 and chronic myelogenous leukemia, BCR-ABL1 positive.